This article was originally published in The Tan Sheet
Wrigley Healthcare Division will be dissolved after discontinuing sales of its Surpass antacid chewing gum March 28. "Despite its quality, Surpass...has not been able to build broad enough popularity with consumers needed to support a brand long-term," 1Wrigley's Web site notes. Healthcare division, which was created two years ago to support Surpass' launch, will be phased out by May, firm says, with employees rejoining parent company. Wrigley's R&D team will "continue to explore the delivery of functional benefits" through chewing gum, with a focus on indications such as throat and cough relief, dental benefits. Firm has attributed poor Surpass sales to difficulty in convincing consumers to switch from liquid/pill antacid forms to gum (2"The Tan Sheet" March 4, 2002, p. 6)...
You may also be interested in...
Wrigley Healthcare is modifying its marketing strategy for Surpass antacid gum to increase consumer trials of the product after its introduction resulted in lower than expected sales
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.